Editorial| Volume 79, ISSUE 4, P355-356, December 2014

Download started.


Bevacizumab and treatment of cervical cancer

  • Sean Kehoe
    Tel.: +44 0121 4148480/0121 5075437.
    Lawson Tait Professor of Gynaecological Cancer, School of Cancer Sciences, Vincent Drive, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
    Search for articles by this author
Published:September 14, 2014DOI:
      Traditionally the focus of systemic therapies in treating malignancies have been cytotoxics that focus on impeding the cell cycle generally through direct DNA damage or other elements associated with mitosis. This has, without doubt, been a successful strategy enhancing the survival prospects for many patients. However, with modern sophisticated facilities to investigate the intricacies of molecular events in malignant cells, there has been a significant interest in the targeting of other cellular and indeed extra-cellular targets to eliminate disease. An equally complex development is the ability to utilise known genetic mutations as a way to induce cell death, specifically PARP inhibitors, which are used in patients with known BRCA mutations and related cancers. Thus the era of individualised and differing therapeutic approaches are upon us. In this context one agent becoming increasingly used is the VEGF [vascular endothelial growth factor] inhibitor bevacizumab. Bevacizumab, in terms of gynaecological malignancies, has been administered for some years to selected patients with ovarian cancer but more recently has been approved by the FDA for use in cervical cancer [ ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Jackson M.W.
        • Rusthoven C.G.
        • Fisher C.M.
        • Schefter T.E.
        Clinical potential of bevacizumab in the treatment of metastatic and locally advanced cervical cancer: current evidence.
        Onco Targets Ther. 2014; 7: 751-759
        • Hashimoto I.
        • Kodama J.
        • Seki N.
        • et al.
        Vascular endothelial growth factor-C expression and its relationship to pelvic lymph node status in invasive cervical cancer.
        Br J Cancer. 2001; 85: 93-97
        • Tewari K.S.
        • Sill M.W.
        • Long 3rd, H.J.
        • et al.
        Monk BJImproved survival with bevacizumab in advanced cervical cancer.
        N Engl J Med. 2014; 370: 734-743